Mark Bresnik

1.4k total citations · 1 hit paper
25 papers, 884 citations indexed

About

Mark Bresnik is a scholar working on Pulmonary and Respiratory Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, Mark Bresnik has authored 25 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Infectious Diseases and 11 papers in Epidemiology. Recurrent topics in Mark Bresnik's work include Cystic Fibrosis Research Advances (13 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Antifungal resistance and susceptibility (11 papers). Mark Bresnik is often cited by papers focused on Cystic Fibrosis Research Advances (13 papers), Inhalation and Respiratory Drug Delivery (12 papers) and Antifungal resistance and susceptibility (11 papers). Mark Bresnik collaborates with scholars based in United States, France and United Kingdom. Mark Bresnik's co-authors include Ramin Ebrahimi, Johan Maertens, Oliver A. Cornely, Raoul Herbrecht, Andrew J. Ullmann, Dietmar Reichert, Stefan W. Krause, M. Aoun, Heinz A. Horst and C. Rieger and has published in prestigious journals such as Blood, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mark Bresnik

22 papers receiving 866 citations

Hit Papers

Liposomal Amphotericin B as Initial Therapy for Invasive ... 2007 2026 2013 2019 2007 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
    2007 486 citations Oliver A. Cornely, Johan Maertens et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Bresnik United States 11 576 568 300 98 90 25 884
E. Biraghi Italy 9 425 0.7× 544 1.0× 78 0.3× 29 0.3× 99 1.1× 10 704
A. Marinus Belgium 9 739 1.3× 849 1.5× 97 0.3× 103 1.1× 252 2.8× 11 994
B Dupont France 12 545 0.9× 636 1.1× 90 0.3× 101 1.0× 71 0.8× 27 802
S. de Marie Netherlands 16 279 0.5× 336 0.6× 67 0.2× 44 0.4× 63 0.7× 22 726
Elisa Furfaro Italy 18 637 1.1× 692 1.2× 84 0.3× 49 0.5× 89 1.0× 27 824
Hernando Patino United States 11 1.2k 2.2× 1.3k 2.4× 114 0.4× 189 1.9× 277 3.1× 13 1.5k
Frieder Fuchs Germany 11 320 0.6× 439 0.8× 70 0.2× 24 0.2× 28 0.3× 31 659
Diana P. Callender United States 9 372 0.6× 410 0.7× 85 0.3× 95 1.0× 92 1.0× 13 725
A. Upton New Zealand 5 415 0.7× 512 0.9× 41 0.1× 96 1.0× 72 0.8× 7 646
Maria J. G. T. Rüping Germany 13 628 1.1× 744 1.3× 53 0.2× 74 0.8× 135 1.5× 19 845

Countries citing papers authored by Mark Bresnik

Since Specialization
Citations

This map shows the geographic impact of Mark Bresnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bresnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bresnik more than expected).

Fields of papers citing papers by Mark Bresnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bresnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bresnik. The network helps show where Mark Bresnik may publish in the future.

Co-authorship network of co-authors of Mark Bresnik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bresnik. A scholar is included among the top collaborators of Mark Bresnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bresnik. Mark Bresnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Donovan, Fariba, Mark Bresnik, Belinda Lovelace, et al.. (2025). Antifungal therapy patterns, healthcare utilization, costs, and mortality in central nervous system and non-central nervous system disseminated coccidioidomycosis across the continuum-of-care. Clinical Microbiology and Infection. 31(6). 1046–1052. 1 indexed citations
2.
Walsh, Thomas J., Craig I Coleman, Giulio Alessandri Bonetti, et al.. (2025). Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective. Antimicrobial Agents and Chemotherapy. 69(10). e0057025–e0057025.
3.
Alexander, Barbara D., Melissa D. Johnson, Mark Bresnik, et al.. (2024). Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis. Open Forum Infectious Diseases. 12(1). ofae747–ofae747.
4.
Alexander, Barbara D., Melissa D. Johnson, Mark Bresnik, et al.. (2024). Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis. Journal of Fungi. 10(12). 876–876. 1 indexed citations
5.
Gilchrist, Francis, S. Bui, Silvia Gärtner, et al.. (2023). ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. Journal of Cystic Fibrosis. 23(1). 80–86. 2 indexed citations
6.
Keating, Claire, Jonathan B. Zuckerman, Pradeep K. Singh, et al.. (2020). Pseudomonas aeruginosaSusceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation. Antimicrobial Agents and Chemotherapy. 65(3). 10 indexed citations
7.
Fayon, Michaël, et al.. (2016). ePS06.5 Post-hoc review of outcomes in patients switching from tobramycin for nebulization solution (TNS) to aztreonam lysine for inhalation (AZLI). Journal of Cystic Fibrosis. 15. S49–S49. 2 indexed citations
8.
Flume, Patrick A., John P. Clancy, George Retsch‐Bogart, et al.. (2016). Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. Journal of Cystic Fibrosis. 15(6). 809–815. 39 indexed citations
9.
10.
Tiddens, Harm A.W.M., K. De Boeck, John Clancy, et al.. (2014). Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Journal of Cystic Fibrosis. 14(1). 111–119. 40 indexed citations
11.
Tullis, D. Elizabeth, Jane L. Burns, George Retsch‐Bogart, et al.. (2013). Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial. Journal of Cystic Fibrosis. 13(3). 296–305. 39 indexed citations
12.
Assael, B.M., Tacjana Pressler, Diana Bilton, et al.. (2012). Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. Journal of Cystic Fibrosis. 12(2). 130–140. 104 indexed citations
13.
14.
LiPuma, John J., Mark Bresnik, Noreen Henig, et al.. (2012). 58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection. Journal of Cystic Fibrosis. 11. S71–S71. 8 indexed citations
15.
16.
17.
Cornely, Oliver A., Johan Maertens, Mark Bresnik, et al.. (2010). Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses. 54(5). e449–55. 47 indexed citations
18.
Cornely, Oliver A., Johan Maertens, Mark Bresnik, et al.. (2009). Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. Journal of Antimicrobial Chemotherapy. 65(1). 114–117. 14 indexed citations
19.
Cornely, Oliver A., Johan Maertens, Mark Bresnik, et al.. (2007). Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases. 44(10). 1289–1297. 486 indexed citations breakdown →
20.
Cordonnier, Catherine, Mark Bresnik, & Ramin Ebrahimi. (2007). Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses. 50(3). 205–209. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Biraghi Breakdown of academic impact, for papers by A. Marinus Breakdown of academic impact, for papers by B Dupont Breakdown of academic impact, for papers by S. de Marie Breakdown of academic impact, for papers by Elisa Furfaro Breakdown of academic impact, for papers by Hernando Patino Breakdown of academic impact, for papers by Frieder Fuchs Breakdown of academic impact, for papers by Diana P. Callender Breakdown of academic impact, for papers by A. Upton Breakdown of academic impact, for papers by Maria J. G. T. Rüping
Rankless by CCL
2026